Ziccum's LaminarPace system for the production of temperature-stable vaccines is already protected by approved patents. However, during ongoing work to further develop and prepare LaminarPace for commercial production, a number of new, innovative solutions have been developed. By submitting two more patent applications for central design elements Ziccum intends to strengthen and extend the protection of the company's unique production method.
Ziccum CEO Göran Conradson: "We are further expanding our Intellectual Property portfolio around LaminarPace, including key details that are important for improved routine production of vaccines. Submitting these applications now gives the opportunity to extend our IP position on the LaminarPace system, laying the foundation for future industrial applications and collaborations. We have strong protection for our LaminarPace technology—demonstrated by several approved patents describing the basic drying method. These new patent applications add another important dimension to our patent protection and exclusivity in the market. It is also proof that we create new values. as we evaluate new vaccines and further develop our commercial-scale production method. "
For more information about Ziccum, please contact:
Göran Conradson: CEO Ziccum AB
Mob: +46 709 61 55 99
Ziccum AB (publ) develops new patented formulations of biological drugs where sensitivity to temperature differences, especially during transportation, currently limits medical and so commercial potential. The company’s patented technology, LaminarPace, develops dry powder formulations of drugs and vaccines that currently only exist in liquid form. By doing so Ziccum can increase the availability of drugs and vaccines in existing markets-and open up new ones.